TMates vs Telos Rx: Flat $199 vs as-low-as $99 GLP-1 options
TMates vs Telos Rx compares two telehealth GLP-1 options: TMates provides compounded semaglutide at a flat $199/month with 24/7 U.S. doctor access and licensed coverage in all 50 states, while Telos Rx advertises semaglutide from as low as $99/month and tirzepatide from as low as $139/month, both subject to approval by a US-licensed provider. Early verdict: choose TMates for consistent flat pricing and continuous physician access; choose Telos Rx if lower starting pricing or access to tirzepatide is your priority and you confirm eligibility.
Key differences at a glance
This comparison centers on five distinctive differences supported by captured evidence: pricing model, medication options, clinician access and approval, geographic coverage, and regulatory status.
Pricing model: flat rate versus variable starting price
TMates advertises a flat $199/month price that remains the same at every dose and emphasizes no step-up fees as dosage escalates. Telos Rx presents lower entry pricing with semaglutide as low as $99/month and tirzepatide as low as $139/month, contingent on clinician approval and subject to the live offer. TMates frames its model as predictable budgeting. Telos Rx frames prices as “as low as” and notes price depends on plan and live eligibility checks.
Medication options: semaglutide only versus semaglutide and tirzepatide
TMates evidence focuses on compounded semaglutide and mentions limited public detail on tirzepatide availability, with no branded Ozempic, Wegovy, or Zepbound. Telos Rx explicitly offers both compounded semaglutide and compounded tirzepatide, stating tirzepatide acts on GLP-1 and GIP and is available from as low as $139/month if a licensed provider approves you. If access to tirzepatide is a deciding factor, Telos Rx lists it as an option; TMates emphasizes its semaglutide program.
Clinician access and approval process
TMates highlights 24/7 access to U.S.-based doctors across all 50 states and virtual check-in appointments for ongoing oversight. Telos Rx specifies that semaglutide and tirzepatide are prescribed only after review by a US-licensed provider and that treatment is available only when a licensed clinician determines it is medically appropriate. TMates positions continuous physician availability as a core feature. Telos Rx stresses clinician review and subject-to-approval pricing and availability.
Geographic coverage and availability
TMates states licensed coverage in all 50 states and that it ships to most states with availability based on medical eligibility. Telos Rx notes that pricing, eligibility, pharmacy, state coverage and renewal terms may change and that treatment availability depends on clinician approval. The captured Telos Rx materials do not list a definitive nationwide coverage claim in the evidence provided.
Regulatory note and compounded medication status
Both sources include the regulatory qualifier that compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness or quality. TMates explicitly includes this regulatory note in its materials. Telos Rx also states compounded semaglutide and tirzepatide are prescription only and not FDA approved.
Comparison table
| Criteria | TMates | Telos Rx |
|---|---|---|
| Starting price | $199/month flat, same at every dose | Semaglutide as low as $99/month; tirzepatide as low as $139/month |
| Medication options | Compounded semaglutide emphasized; limited public detail on tirzepatide | Compounded semaglutide and compounded tirzepatide offered, subject to approval |
| Clinician access | 24/7 U.S. doctor access and virtual check-ins | Treatment prescribed after review by a US-licensed provider; clinician approval required |
| Geographic coverage | Licensed coverage in all 50 states; ships to most states, availability based on medical eligibility | State coverage and availability may change; subject to clinician and plan |
| Regulatory status | Compounded medications not FDA approved | Compounded medications not FDA approved |
How to choose between TMates vs Telos Rx
If predictable, dose-independent pricing and continuous physician availability are your priorities, TMates supports that with a flat $199/month program and 24/7 U.S. doctor access in all 50 states. If lower advertised starting price or explicit access to compounded tirzepatide is important and you will confirm eligibility with a clinician, Telos Rx lists semaglutide from as low as $99/month and tirzepatide from as low as $139/month, both subject to approval.
Final verdict
TMates vs Telos Rx boils down to price predictability and nonstop clinician access versus lower entry pricing and an explicit tirzepatide offering that requires clinician approval. Both note compounded medications are not FDA approved. Choose TMates if you want flat pricing at every dose and 24/7 U.S. doctor access. Choose Telos Rx if you prioritize lower starting pricing or the option of tirzepatide and will confirm eligibility with a US licensed provider.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →